ReviewMedicina (Kaunas, Lithuania)2026
Dual-Function Antimicrobial Peptides as a Prospective Strategy Against Peri-Implantitis: Bridging Cutaneous Wound Healing and the Peri-Implant Soft-Tissue Seal.
Review in Medicina (Kaunas, Lithuania), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Peri-implantitis, a biofilm-driven inflammatory disease that causes progressive loss of the bone supporting dental implants, is common and difficult to treat: mechanical debridement cannot fully decontaminate the implant surface, and antibiotic adjuncts act non-selectively while promoting resistance. Antimicrobial peptides (AMPs) have emerged as a promising preventive strategy. As cationic, membrane-disrupting molecules they kill a broad spectrum of organisms with a low propensity to select for resistance, and as host-defense peptides they additionally modulate inflammation and promote epithelial and connective-tissue repair. This review examines AMP-functionalized titanium as a prospective strategy against peri-implantitis through a dermatological lens, drawing on the established roles of the cathelicidin LL-37 and the β-defensins in cutaneous and oral wound healing. We argue that the peri-implant transmucosal interface behaves as a healing epithelial barrier, so that a single class of host-defense peptides can address two goals usually pursued separately-suppressing the peri-implant biofilm and reinforcing the soft-tissue seal. Because peri-implant disease initiates at the transmucosal region, we give particular attention to the abutment or transmucosal collar as the primary sealing target, and we consider how the concept extends to zirconia and hybrid components. The evidence assembled here, however, is predominantly preclinical, derived from in vitro and animal studies, and does not yet demonstrate clinical prevention of peri-implantitis in patients. After surveying peri-implant epidemiology, microbiology, AMP biology, surface-engineering strategies, and the in vivo evidence, we appraise the translational barriers-stability, cytotoxicity, cost, regulation, and the absence of human trials-that remain. We conclude that biologically intelligent, multifunctional peptide coatings represent a rational direction for next-generation implant surfaces.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.